Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Melissa A. Lowder

Structural Differences Between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors

Journal of the American Chemical Society

English

Bipartite Tetracysteine Display Reveals Allosteric Control of Ligand-Specific EGFR Activation

English

Related publications

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research

Oncology

2019

English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation

English

In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Molecular Cancer Therapeutics

Cancer Research

Oncology

2014

English

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

Expert Review of Anticancer Therapy

Oncology

Pharmacology

2019

English

P1.13-10 Aurora Kinase a Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

Journal of Thoracic Oncology

English

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

English

Functional Differences Between Wild-Type and Mutant-Type BRCA1-associated Protein 1 Tumor Suppressor Against Malignant Mesothelioma Cells

English

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Cancer Research

Oncology

2017

English

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Melissa A. Lowder

Structural Differences Between Wild-Type and Double Mutant EGFR Modulated by Third-Generation Kinase Inhibitors

Bipartite Tetracysteine Display Reveals Allosteric Control of Ligand-Specific EGFR Activation

Related publications

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

In Vitro and in Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Third Generation EGFR TKI Landscape for Metastatic EGFR Mutant Non-Small Cell Lung Cancer (NSCLC)

P1.13-10 Aurora Kinase a Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer

Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer

Functional Differences Between Wild-Type and Mutant-Type BRCA1-associated Protein 1 Tumor Suppressor Against Malignant Mesothelioma Cells

Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors

Overcoming T790M Mutant Small Cell Lung Cancer With the Third-Generation EGFR-TKI Osimertinib